Comparative Pharmacology
Head-to-head clinical analysis: CERETEC versus THALLOUS CHLORIDE TL 201.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CERETEC versus THALLOUS CHLORIDE TL 201.
CERETEC vs THALLOUS CHLORIDE TL 201
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Technetium-99m exametazime (Ceretec) is a lipophilic radiopharmaceutical that crosses the blood-brain barrier and is taken up by brain tissue in proportion to regional cerebral blood flow. Once inside cells, it undergoes intracellular conversion to a hydrophilic form, trapping it in the brain and allowing SPECT imaging.
Thallous chloride Tl-201 is a potassium analog that is taken up by viable myocardial cells via the Na+/K+ ATPase pump. Its distribution reflects regional myocardial blood flow and cell viability. In areas of ischemia or infarction, uptake is reduced, creating a perusion defect.
555-740 MBq (15-20 mCi) intravenously as a single dose for SPECT imaging.
111-148 MBq (3-4 mCi) intravenous injection for myocardial perfusion imaging; imaging begins 5-10 minutes post-injection.
None Documented
None Documented
Terminal: 6 hours (range 4–8 h); clinical: supports twice-daily dosing in nuclear medicine studies.
Terminal elimination half-life: approximately 73 hours. Clinical context: The long half-life allows for delayed imaging (e.g., redistribution imaging for thallium-201 myocardial perfusion scans).
Renal: 40% unchanged; biliary/fecal: 60% (as metabolites and parent compound).
Renal: approximately 70% over 10 days; fecal: less than 30% over 10 days.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical